alexa The Effect of Different Contraceptive Drugs on the Lipid Profile of Brazilian Women | OMICS International
ISSN : 2153-2435
Pharmaceutica Analytica Acta

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

The Effect of Different Contraceptive Drugs on the Lipid Profile of Brazilian Women

Bianca Stocco1*, Helen F. Fumagalli1, Silvio Antônio Franceschini2, Cleni Mara Marzocchi Machado1 and Maria Regina Torqueti Toloi1

1Department of Clinical, Toxicological and Bromatological Analysis, Faculty of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo,14040-903, Ribeirão Preto, Brazil

2Department of Obstetrics and Gynecology, Faculty of Medicine of Ribeirão Preto, University of São Paulo, 14049-900, Ribeirão Preto, Brazil

*Corresponding Author:
Bianca Stocco
Avenida do Cafe, S/N, Bloco M, Sala 52
Ribeirao Preto, Sao Paulo, ZIP 14040-903, Brazil
Tel: + 55-16-3602-4220/4208
Fax: + 55-16-3602-4725
E-mail: [email protected]

Received date: December 18, 2012; Accepted date: January 23, 2013; Published date: January 28, 2013

Citation: Stocco B, Fumagalli HF, Franceschini SA, Marzocchi Machado CM, Torqueti Toloi MR (2013) The Effect of Different Contraceptive Drugs on the Lipid Profile of Brazilian Women. Pharmaceut Anal Acta 4:208. doi: 10.4172/2153-2435.1000208

Copyright: © 2013 Stocco B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Pharmaceutica Analytica Acta


Purpose: Evaluating the concentration of the lipoproteins HDL, LDL, VLDL, triglycerides and total cholesterol in the serum of women who use oral combined contraceptives containing anti-androgenic progestogen in comparison to control group.
Method: Cross-sectional study developed with 47 women (18 to 30 years), distributed into two groups of patients who used oral contraceptive drugs containing 20 or 30 μg de Ethinylestradiol (EE) combined to Drospirenone (DRSP), compared to a control group. The serum levels of lipids (Total cholesterol, Triglycerides and HDL) were quantified through Trinder’s method. The levels of LDL and VLDL were obtained through mathematical formulas.
Results: In the users of DRSP/30EE there was an increase in the levels of total cholesterol, triglycerides,
HDL and VLDL in relation to control group. In the users of DRSP/20EE, there was an increase in the levels of total cholesterol and HDL.
Conclusion: The anti-androgenic progestogen drospirenone was not effective to counterbalance the beneficial effect of the estrogen on the levels of the lipoprotein HDL.


Under physiological conditions, endothelial cells are responsible for the maintenance of vascular integrity. Thus, these cells prevent the activation and aggregation of inflammatory cells and platelets, promote fibrinolysis and control vascular tonus. These antiatherogenic properties of the endothelial cells are controlled by the enzyme nitric oxide synthase (eNOS), which is responsible for the synthesis and release of nitric oxide (NO). The release of this molecule inhibits the expression of inflammatory cytokines and adhesion molecules (ICAM and VCAM), prevents the activation of platelets and promotes vasodilation [1]. Nevertheless, the continuous exposure of the endothelium to risk factors such as smoking, hypertension, obesity, inflammation, insulin resistance and hyperlipidemia, may lead to endothelial dysfunction, which contributes to the formation of atherosclerotic plaque and cardiovascular diseases [2].

Many studies have observed a greater incidence of atherosclerosis and cardiovascular diseases in men in comparison to women of the same age. However, the same result is not observed for women in menopause, due to the cardio protective effect of estrogen [3,4]. In vitro studies have demonstrated that estrogen exerts favorable actions on the endothelium, for instance, stimulating the production of nitric oxide [5] and reducing the expression of adhesion molecules [6]. Moreover, estrogen is capable of promoting in vivo protective actions, such as the decrease of soluble adhesion molecules [7] and reduction of hepatic triglyceride lipase, which degrades HDL (High Density Lipoprotein), stimulating, thus, the production of HDL cholesterol and reducing the production of LDL (Low Density Lipoprotein) cholesterol [8]. Epidemiological studies developed in the last five decades demonstrated that the levels of HDL cholesterol are inversely related to the clinical events that predispose atherosclerosis and cardiovascular diseases, whereas the levels of LDL cholesterol are directly related to these events [9,10]. HDL protects against cardiovascular diseases through the regulation of the efflux of cholesterol from tissue and modulation of the inflammation. It may also remove cholesterol from macrophages, which are believed to be one of the mechanisms through which this molecule may protect against atherosclerosis [11]. Other properties include antioxidant and vasoprotective effects [12].

Estrogen, the cardio protective hormone, is also present in medications with contraceptive action, such as oral combined contraceptives, containing synthetic progesterone and estrogen in their formulation, which are responsible for the inhibition of the natural production of these hormones by the ovaries [13]. Despite of the protective effect developed by the estrogen, progesterone may exert adverse influence on the metabolism of the lipids [14].

Progesterone administered solely or combined with estrogen may reduce the plasma concentration of triglycerides and HDL cholesterol in women in pre and post menopause [15].

Androgenic progestogens, derived from testosterone, have greater interference in the beneficial alterations of estrogen over the lipid profile, since they promote a reversion in the increase of HDL due to an increase in the activity of hepatic lipases [16].

In this sense, the purpose of this study was to evaluate the effect of two formulations of contraceptive medications, containing different doses of estrogen and drospirenone progestogen, spironolactonederived progesterone, with anti-androgenic and diuretic effects [17] on the lipid profile of Brazilian women.

Materials and Methods

Clinical protocol

This study had the voluntary participation of 47 healthy women, who were students at the University of São Paulo, Campus of Ribeirão Preto, and users of the Gynecology and Obstetrics Department of the Basic Health Unit at the University Hospital of Ribeirão Preto School of Medicine (FMRP-USP). The volunteers were distributed into three groups, namely: a control group, consisting of women who do not use a hormonal contraceptive method; and two groups made of women who use contraceptives containing 3 mg of drospirenone (DRSP) combined with 30 or 20 mcg of ethinylestradiol (EE), as indicated by the following diagram (Figure 1).


Figure 1: Study design. DRSP, Drospirenone; EE, ethinylestradiol; (n), number of participants.

Patients were selected according to the inclusion and exclusion criteria adopted. Inclusion criteria were: age between 18 and 30 years, body mass index (BMI) ≤ 30 Kg/m2, user or non-user (control group) of contraceptive for a minimum period of six months and a maximum period of 24 months. Pregnant patients, smokers, patients under the prescription of anti-inflammatory medication or with personal history of cardiovascular disease, hypertension, thrombosis, hepatopathies, diabetes or autoimmune diseases were excluded from the study. The volunteers answered a questionnaire that aimed at obtaining information such as age, body mass index (BMI), frequency in the practice of physical exercise and family history of thromboembolic disease (Table 1). Blood samples were collected in the morning with a butterfly needle and, after collection, centrifuged to obtain serum, whose aliquots were placed in polyethylene tubes and stored at -70°C for the maximum period of six months. After this period, serum samples were thawed in bain-marie at 37°C for the development of laboratorial assays.

Variable Control (n=20) Group II (n=16) Group III (n=11) p value
Age (years) Mean (SD) 26.3(2.4) 24.7(2.4) 23.2(3) 0.01
BMI (Kg/m2) Mean (SD) 22.4(2.9) 22.9(2.7) 21.3(2.8) <0.05
Exercise % (n) 37.5(6) 43.8(7) 18.8(3) <0.05
Thrombosis % (n) 46.7(7) 33.3(5) 20(3) <0.05

Table 1: Characteristics of the women involved in the study.

Laboratorial variables

The biochemical variables total cholesterol, HDL cholesterol and triglycerides were quantified in the serum of the patients with the assistance of the automated device BT 3000 plus Wiener Lab®, through the enzymatic reaction of Trinder’s colorimetric method, using the Kit Wiener lab (Rosario-Argentina). Levels of LDL cholesterol were calculated through the formula of Friedewald: [LDLcholesterol]=[ total cholesterol]-[HDL cholesterol]- [triglycerides]/5. Levels of VLDL-cholesterol were calculated through the formula: [VLDL]=[triglycerides]/5 [18].

Statistical analyses

After verifying the normal distribution of the samples involved in this study, the population means of the quantitative variables age, BMI, total cholesterol, LDL, VLDL, HDL and triglycerides in the three groups of volunteers were compared through the analysis of variance (ANOVA). Bonferroni’s posttest was used in order to compare the quantitative variables among the groups. The Chi test 2 was used to compare the mean of the qualitative variables frequency in the practice of physical exercise and family history of thrombosis among the three groups. In all analyses the program SPSS version 17 (PASW Statistics) was used, and the significance level adopted was of 5% (α= 0.05). The confidence interval of the mean was calculated with a significance level of 95%.


The characteristics of all 47 women, who participated in this study and were divided into three groups, are presented in table 1.

Regarding the age of the participants, it is possible to identify that older patients are found in the control group, whereas younger patients are in group III. The age difference between these two groups was found significant (p=0.01). Group III has patients with lower BMI, frequency in the practice of physical exercise and personal or family history of thrombosis. Group II has patients with higher frequency in the practice of physical exercise and control group comprises patients with higher personal or family incidence of thrombosis.

The results obtained through the analyses of the biochemical variables are described in table 2.

Variable Control (n=20) Group II (n=16) Group III (n=11) p value
HDL Mean (SD) (CI) 48.8(9) (44.5-53) 62.8(6.5)  (59.2-66.3) 64.2(2.7) (55.6-72.7) 0.0
LDL Mean (SD) (CI) 98.5(19) (89.5-107.4) 101.8(26) (87.7-115.8) 104.9(22) (89.8-120) <0.05
VLDL Mean (SD) (CI) 15.08(11.8) (9.5-20.6) 25.7(8.5) (21.2-30.3) 22.7(9.4) (16.4-29.1) 0.01
Total Chol. Mean (SD) (CI) 162.4(24) (151.1-173.7) 190.3(31.1) (173.7-207) 192(23.4) (176.3-207.8) 0.01
Triglycerides Mean (SD) (CI) 75.4(79) (47.8-103) 128.8(48) (106-151.6) 114(47) (82.3-145.5) 0.01

Table 2: Biochemical variables analyzed in this study.

In the results obtained with the analyses of the biochemical variables, it is possible to identify that the control group has lower levels of HDL cholesterol in comparison to the groups that use DRSP/30EE and DRSP/20EE (p=0.0). For the variable LDL cholesterol, no significant differences were found in the levels of this lipoprotein among the studied groups. Regarding VLDL cholesterol, it is possible to observe that the group using DRSP/30EE presents higher levels of this lipoprotein in relation to control group (p=0.01). In the quantification of total cholesterol, control group presents lower levels in comparison to the other groups, made of contraceptive users (p=0.01). As for triglycerides, it is observed that control group has lower levels in relation to the group using DRSP/30EE (p=0.01).


Hyperlipidemia is among the risk factors that may promote endothelial dysfunction, leading to the development of atherosclerosis and cardiovascular diseases. High concentrations of oxidized LDL may stimulate the production of pro-inflammatory molecules such as VCAM, ICAM and E-selectin, and, therefore, initiate damage to the endothelium [19]. Different from the action of the lipoprotein LDL, HDL protects against cardiovascular diseases through the regulation of the efflux of cholesterol from tissue and modulation of the inflammation [11]. The hormone estrogen, present in oral combined contraceptives, stimulates the production of HDL and reduces the production of LDL cholesterol [8], preventing damage to the endothelium. Despite of this beneficial action of the estrogen to the endothelium, the hormone progesterone, which is also present in oral combined contraceptives, may reduce the plasma concentration of HDL [15].

The literature points out those androgenic progestogens have a greater capability of counterbalancing the beneficial effects of the estrogen on the lipid profile [16]. This study evaluated the levels of lipoproteins, total cholesterol and triglycerides in the serum of women who use oral combined contraceptives containing the progestogen Drospirenone, which has anti-androgenic and diuretic effect [17]. In the study design, the group hypothesized that, due to its antiandrogenic character, the progestogen drospirenone is not effective to change the beneficial actions provided by the estrogen to the lipid profile (Figure 1).

In this study, higher levels of HDL were found in the serum of users of DRSP/20EE and DRSP/30EE, in comparison to control group. This finding agrees to the literature [20] and shows that despite of the presence of the progestogen, the levels of HDL for this group are higher than the levels of this lipoprotein in the control group. Different from this finding, a study developed with 48 women treated with contraceptive containing androgenic progestogen (LNG/20EE and LNG/30EE) observed decrease in the levels of the lipoprotein HDL in comparison to basal analyses [21]. Levels of VLDL, in this study, are higher for patients who use DRSP/30EE in comparison to control group. For users of DRSP/20EE, high levels of VLDL are also observed in relation to control group, but this difference was not considered to be significant. The higher levels of VLDL found in the groups using contraceptives may be also attributed to the hormone estrogen, which can increase the hepatic secretion of this lipoprotein [22]. Levels of triglycerides were also higher in women who use contraceptives when compared to the control group, since VLDL is triglyceriderich lipoproteins [22]. Nevertheless, the increase in the production of VLDL and, consequently, triglycerides, contributes to increase the clearance of the VLDL particles, since these are rapidly converted into LDL [23]. After being converted into LDL, HDL will promote the efflux of the cholesterol from tissue to the liver, where LDL can be converted into bile acid and secreted through the bile [24]. The levels of total cholesterol were found significantly higher in groups using contraceptives in relation to the control group. Total cholesterol sums the lipoproteins HDL, LDL, and VLDL, and probably presents higher levels in contraceptive users due to the increase observed in the levels of VLDL and HDL.

In face of these findings, the authors conclude that the antiandrogenic progestogen drospirenone was not effective to counterbalance the beneficial effect of the estrogen on the levels of the lipoprotein HDL, which confirms their hypothesis in relation to contraceptives containing androgenic progestogen.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

  • 4th International Conference on Drug Discovery, Designing and Development
    June 27-28, 2018 Vancouver, Canada
  • 18th World Pharma Congress
    October 18-19, 2018 Warsaw, Poland

Article Usage

  • Total views: 11703
  • [From(publication date):
    January-2013 - Jun 23, 2018]
  • Breakdown by view type
  • HTML page views : 7923
  • PDF downloads : 3780

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7